comparemela.com

Latest Breaking News On - Abbvie deutschland gmbh co - Page 5 : comparemela.com

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

/PRNewswire/ AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO).

United statesRheinland pfalzLemzoparlimab lemzoEpcoritamab epcoRituximab venVenclyxto smOsimertinib osiTelisotuzumab vedotin telisoMohamed zakiTelisotuzumab vedotinNavitoclax monotherapyAbbvie companyAmerican society of clinical oncologyJanssen biotech incEuropean hematology associationUs national library of medicine

Patent Antibody Case Law Continues To Mature - Intellectual Property

Explosive growth of antibody technology and therapeutics over the past three decades has driven development of antibody-centric patent case law across several fronts.

United statesJames evansEli lillyIdenix pharmsJohns hopkins universityPsys incJanssen biotech incImmunex corpUnited states district courtHybritech incPatent officeAriad pharm incWyeth cordis corpAbbvie deutschland gmbh coResolution at regeneron pharmaceuticalsJuno therapeutics inc

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn s Disease

/PRNewswire/ AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEL, a Phase 3 induction study, showing upadacitinib (45 mg once daily).

United statesMichael severinoGastroenterol hepatolAccess economics ptyDrug administrationExchange commissionEu european medicines agencyAbbvie incAbbvie deutschland gmbh coCrohn colitis foundation of americaCrohn disease programDisease activity indexEfficacy resultsMedicines agencyUpadacitinib phaseImportant safety

AbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn s and Colitis Organization (ECCO)

/PRNewswire/ AbbVie (NYSE: ABBV) will present further analyses on HUMIRA® (adalimumab) and the investigational uses of risankizumab (SKYRIZI®) and.

Chiedzo mpofuRemo panaccioneAnn gastroenterolGastroenterol hepatolAccess economics ptyAbbvie ltdEuropean commissionBoehringer ingelheimDrug administrationExchange commissionUniversity of calgaryEuropean unionAbbvie incColitis organisationAbbvie deutschland gmbh coCrohn colitis foundation of america

AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U S Food and Drug Administration (FDA) and European Medicines Agency (EMA)

/PRNewswire/ AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approvals for upadacitinib (RINVOQ®, 15 mg once daily) to the.

United statesThomas hudsonEuropean commissionDrug administrationExchange commissionEuropean unionAbbvie incArthritis foundationEuropean medicines agencyAbbvie deutschland gmbh coNew drug applicationImportant safetyMississippi riverFull prescribing informationImportant safety informationAllergan aesthetics

vimarsana © 2020. All Rights Reserved.